SLC40A1 and lobular neoplasia: In this regard, VIT-2763 (oral ferroportin inhibitor), synthetic human hepcidin and its agonists that are currently in clinical trials (ClinicalTrials.gov: NCT04364269, NCT03381833, and NCT03165864) could be tested as adjuvants to immunosuppressive therapy for LN.